Lowering of lipoprotein(a) level under niacin treatment is dependent on apolipoprotein(a) phenotype

Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy

New England Journal of Medicine · 2011 · 2.9K citations · Full text

Pharmacy, Internal Medicine, Pharmacotherapy +9

Lipoprotein(a) as a cardiovascular risk factor: current status

Børge G. Nordestgaard, M. John Chapman, Kausik K. Ray et al. · European Heart Journal · 2010 · 1.8K citations · Full text

Medicine, Cardiology, Clinical Cardiology +16

Lp(a) glycoprotein phenotypes. Inheritance and relation to Lp(a)-lipoprotein concentrations in plasma.

Gerd Utermann, H. Menzel, H.G. Kraft et al. · Journal of Clinical Investigation · 1987 · 887 citations · Full text

Life Sciences, Biochemistry, Molecular Biology +14

HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment

Lixin Jiang, Jemma C. Hopewell, Jing Li et al. · European Heart Journal · 2013 · 673 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +8

Relationship of Apolipoproteins A-1 and B, and Lipoprotein(a) to Cardiovascular Outcomes

John J. Albers, April Slee, Kevin D. O’Brien et al. · Journal of the American College of Cardiology · 2013 · 312 citations

Life Sciences, Biochemistry, Cardiology +14